Migration of people from HCV endemic countries is a public health issue for the French healthcare system. The PRECAVIR study focused on migrant patients and provides a multidisciplinary, patient-centered approach to treat chronic HCV-infected migrants through a systematic screening program. Between 2007 and 2017, 101 (2.98%) out of 3386 consecutive adult migrants attending two primary health care settings in Créteil, France, tested positive for HCV. The median age was 44.5 years old and 55% were women. Patients were mainly from sub-Saharan Africa, Eastern Europe, and Asia. Seventy-four patients were undocumented migrants and 25 were asylum seekers. Eighty-four (83%) patients were unaware of their serological status. All patients were offered referral to a specialist in the same setting. HCV RNA testing was performed in 88 (87%) of the patients who tested anti-HCV positive. Forty-nine (57%) were chronically infected, while 39 (43%) had an undetectable viral load. All patients were treatment-naïve. More than half patients had access to treatment. Before 2014, thirteen patients were treated with pegylated interferon and ribavirin, and an SVR was achieved in 8 (61.5%) of them. By 2017, 17 patients had begun oral, direct-acting antiviral treatment. An SVR was achieved in 16 of 17 patients (93%). However, all patients not initially eligible for treatment were lost to follow-up. This study showed the effectiveness of a coordinated care network when anti-HCV testing, linkage- to-care, and treatment are organized for a migrant population in the same setting as long as universal treatment makes a test and treat policy possible. This article is protected by copyright. All rights reserved.